Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy

NCT02049047 | Completed Phase 2

• 1 other identifier: ONC-2010-001
• Study Type: interventional
• Target: 41
• Locations: 1 country
• Sites: 1

Brief Summary

Given the high expression of IGF-1R and pAKT proteins in thymoma tissues, able to sensitize tumors to mTOR inhibition, and the anticancer activity of the mTOR inhibitors, clinical evaluation in thymoma and thymic carcinoma seems to be very interesting. Patients will receive continuous treatment with oral everolimus 10 mg once daily. Efficacy and safety profile of Everolimus will be evaluated.

Conditions

Thymoma and Thymic Carcinoma

Keywords

thymoma thymic carcinoma

Outcome Measures

Primary Outcomes (1)

• disease control rate

  disease control rate (DCR), considered as complete response (CR) plus partial response (PR) plus stable disease (SD), of Everolimus monotherapy

  6 months

Secondary Outcomes (6)

• PFS

  6 months

• Duration of Response

  6 months

• OS

  6 months

• FDG-PET imaging relations

  6 weeks

• safety profile

  6 months

Study Arms (1)

Everolimus

EXPERIMENTAL

oral everolimus

Drug: Everolimus

Interventions

Everolimus DRUG

Everolimus will be orally administered at the dosage of 10 mg once daily. Each cycle will be considered as 21 days of treatment. Tumor assessment will be done every two cycles.Treatment should be administered until documented disease progression, unacceptable toxicity, or patient refusal.

Also known as: Afinitor

Everolimus

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Histological diagnosis of invasive recurrent or metastatic thymoma or thymic carcinoma confirmed by pathologist.
• At least one prior platinum-containing chemotherapy regimen. There is no limit to the number of prior chemotherapy regimens received. Progressive disease should have been documented before entry into the study.
• Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as greater than 20 mm with conventional techniques or as greater than 10 mm with spiral CT scan.
• Patients must have recovered from toxicity related to prior therapy to at least to grade 1 (defined by CTCAE 3.0).
• No major surgery, radiation therapy, chemotherapy, biologic therapy (including any investigational agents), or hormonal therapy (other than replacement), within 4 weeks prior to entering the study.
• Life expectancy of at least 3 months.
• Performance status (ECOG)\<=2
• Negative pregnancy test (if female in reproductive years)
• Adequate organ and marrow function (as defined below)
• Leukocytes \>=3,000/mm, Absolute neutrophil count \>=1,500/mm, Hemoglobin\>= 9 g/dL, Platelets\>= 100,000/mm, Total bilirubin \>= 1.5 x institutional upper limit of normal (ULN), AST(SGOT)/ALT(SGPT)\>= 3 x institutional ULN (5x if LFT elevations due to liver metastases, )Creatinine \<= 1.5 x institutional ULN

You may not qualify if:

• Patients with symptomatic brain metastases. However, patients who have had treatment for their brain metastases and whose brain metastatic disease status has remained stable for at least 3 months without steroids may be enrolled at the discretion of the investigator.
• Major surgery, other than diagnostic surgery, within 4 weeks prior to treatment
• Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
• Pregnant or breast feeding women
• Previous (within the last 5 years) or current malignancies at other sites, except for adequately treated basal cell or squamous cell skin cancer or in situ carcinoma of the cervix uteri
• Current enrollment in or participation in another therapeutic clinical trial within 4 weeks preceding treatment start.
• Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgement of the Investigator, would make the patient inappropriate for entry into this study or could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor.

Sponsors & Collaborators

• Armando Santoro, MD: lead

Study Sites (1)

Istituto Clinico Humanitas

Rozzano, MI, 20089, Italy

Location

Related Publications (1)

• Zucali PA, De Pas T, Palmieri G, Favaretto A, Chella A, Tiseo M, Caruso M, Simonelli M, Perrino M, De Vincenzo F, Toffalorio F, Damiano V, Pasello G, Garbella E, Ali M, Conforti F, Ottaviano M, Cioffi A, De Placido S, Giordano L, Bertossi M, Destro A, Di Tommaso L, Santoro A. Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy. J Clin Oncol. 2018 Feb 1;36(4):342-349. doi: 10.1200/JCO.2017.74.4078. Epub 2017 Dec 14.

  PMID: 29240542 DERIVED

MeSH Terms

Conditions

Thymoma

Interventions

Everolimus

Condition Hierarchy (Ancestors)

Neoplasms, Complex and Mixed; Neoplasms by Histologic Type; Neoplasms; Thymus Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Lymphatic Diseases; Hemic and Lymphatic Diseases

Intervention Hierarchy (Ancestors)

Sirolimus; Macrolides; Lactones; Organic Chemicals

Study Officials

• Armando Santoro, MD

  Istituto Clinico Humanitas

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: principal Investigator

Study Record Dates

• First Submitted: May 27, 2013
• First Posted: January 29, 2014
• Study Start: February 1, 2011
• Primary Completion: April 1, 2014
• Study Completion: January 1, 2019
• Last Updated: September 10, 2022

Record last verified: 2022-09

Data Sharing

• IPD Sharing: Will not share

Locations

IT (1)